JPRN-UMIN000016494招募中未知
A Pilot Study of Dasatinib for Relapsed or Refractory ABL1/PDGFRB Rearrangemennt Positive Ph-like Acute Lymphoblasic Leukemia - D-APPLE STUDY
ational Center for Child Health and Development0 个研究点目标入组 3 人开始时间: 2015年2月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 20years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe CNS or gastrointestinal hemorrhage (grade 2 or higher in CTCAE ver4.0) 2) Patients with severe fluid retention (grade 2 or higher in CTCAE ver4.0) 3) QTc is more than 0.45 seconds 4) Patients with uncontrollable infection (including those with active tuberculosis or positive HIV antibody) 5) Patient with a history of organ transplantation other than stem cell transplantation 6) Patient with uncontrollable diabetes mellitus 7) Patients with history of primary or acquired immunodeficiency 8) Patients who are pregnant 9) Patient with 21-trisomy 10) Patient with severe mental retardation 11) Patients with any other inappropriate status judged by physician
研究者
相似试验
已完成
2 期
Dasatinib plus Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic LeukaemiaACTRN12607000609459Australasian Leukaemia and Lymphoma Group (ALLG)20
进行中（未招募）
不适用
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-BEBristol-Myers Squibb International Corporation300
进行中（未招募）
不适用
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-CZBristol-Myers Squibb International Corporation300
已完成
1 期
Dasatinib in Relapsed or Refractory Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00550615University of Nebraska38
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50